Starting a women’s hormone and menopause telemedicine clinic takes roughly 12 weeks if you already hold an NP, PA or physician license. The gating items are a clinical protocol you can defend to your board, a decision on FDA-approved versus compounded hormones, a DEA registration if you will prescribe testosterone, an EHR with e-prescribing, a lab account and a pharmacy that ships to every state you serve. Perimenopause and menopause care is widely reported to be one of the most under-served areas of adult medicine, and because management is ongoing rather than episodic it fits a cash-pay monthly model well. This is a 2026 planning guide, not medical or legal advice; rules vary by state and change, so confirm every point with your licensing board and counsel.
Why menopause care works as a cash-pay telemedicine model
The care gap is well documented: most clinicians received little formal menopause training, and many women with vasomotor, sleep, mood or genitourinary symptoms are never offered treatment. Two decades of caution after the 2002 Women’s Health Initiative publicity began to reverse in 2025, when the FDA announced it would remove the broad boxed warnings on cardiovascular disease, breast cancer and dementia from systemic menopausal hormone therapy labels; the first revised labels were reported approved in early 2026. Treat that as “reported in 2025, confirm the current label for each product you prescribe”, but the direction is clear and demand has followed it.
A woman who starts hormone therapy in her late forties may stay on it for years with periodic adjustment, so revenue is a monthly or quarterly management relationship rather than a single consult, and most visits are conversation and review, which suits video care.
Clinical scope and protocols at a high level
A typical women’s hormone clinic treats the perimenopause transition and postmenopause: vasomotor symptoms, sleep and mood disturbance tied to hormone change, genitourinary syndrome of menopause, and sexual-desire concerns. It does not manage cancer survivors without specialist co-management, it screens out the contraindications to estrogen listed in current guidance, and it refers abnormal bleeding or pelvic findings for in-person evaluation.
FDA-approved hormone therapy versus compounded bioidentical hormones
The term “bioidentical” causes confusion your protocol should resolve in writing. FDA-approved products include bioidentical molecules: transdermal and oral estradiol, micronized progesterone and vaginal estrogen are all approved, labeled and dose-consistent. Compounded bioidentical hormone therapy (cBHT) means a 503A compounding pharmacy prepares creams, troches or pellets to an individual prescription; these are not FDA-approved, and a 2020 National Academies report recommended limiting them to patients with a documented allergy to an approved product’s ingredient or a need for a dosage form no approved product provides. The FDA opened a further public docket on compounded hormone therapy in 2025. The defensible position is approved products first, compounded preparations only with a documented reason, and never a claim that compounded hormones are safer or more “natural”.
Testosterone for women
There is no FDA-approved testosterone product for women in the United States. The 2019 global consensus position statement supports testosterone only for postmenopausal women with hypoactive sexual desire disorder, at doses that keep blood levels in the premenopausal physiologic range, and found no support for its use in mood, cognition, bone or body composition. In practice that means a fraction of a male-labeled transdermal product or a compounded low-dose cream, off-label and consented as such. Testosterone is a Schedule III controlled substance, so each prescriber needs a DEA registration, any state controlled-substance registration, EPCS where mandated and a PDMP check where required. Federal rules allowing controlled substances to be prescribed by telemedicine without a prior in-person exam have been extended through December 31, 2026 under a temporary rule, with a special-registration framework proposed but not final; confirm the current status before launch and keep an in-person pathway in your protocol.
Baseline labs and when they are and are not required
Current guidance treats perimenopause and menopause in a woman over 45 with typical symptoms as a clinical diagnosis; FSH and estradiol fluctuate so much during the transition that they rarely change management. Labs earn their place in three situations: women under 45 (especially under 40, where premature ovarian insufficiency needs confirmation), atypical presentations where thyroid disease, anemia or pregnancy is plausible, and safety screening before and during treatment. A typical baseline panel is therefore modest (CBC, metabolic panel, lipids, A1c, TSH), with additional tests driven by history rather than a reflexive full hormone panel. If you prescribe testosterone, a baseline total testosterone and SHBG, repeated after the first weeks and periodically after, documents that levels stay physiologic.
Monitoring cadence and informed consent
A common cadence is a first follow-up six to twelve weeks after starting or changing therapy, then every three to six months during the first year, then at least annually with an explicit review of whether continued treatment still makes sense. Unscheduled bleeding, new breast findings or thromboembolic symptoms trigger an off-cycle visit and referral. Informed consent should cover, in plain language, the risks and benefits of systemic hormone therapy and how they vary with age and time since menopause; that any compounded preparation is not FDA-approved; that testosterone use is off-label; the telemedicine items your state requires; and how emergencies are handled. Have it signed before the first prescription and re-affirmed when the regimen changes.
Regulatory and compliance specifics for this specialty
Licensure and practice authority. The patient’s location is the place of practice, so you need a license in every state where patients sit, plus whatever collaboration or supervision that state requires of NPs and PAs. Start in your home state and add states deliberately.
Compounding relationships. Work only with pharmacies that hold the nonresident license required by each destination state, ask which products are compounded under 503A versus sourced from a 503B outsourcing facility, and keep every prescription individualized; standing “menu” orders attract scrutiny. Pellets require an in-person procedure and professional guidance has been cautious about them.
Advertising and privacy. You may market menopause and perimenopause care. You may not advertise compounded hormones as FDA-approved, state that testosterone is approved for women, promise outcomes, or use testimonials in ways your state board restricts. HIPAA applies in full, including business associate agreements with every vendor that touches patient data and no retargeting pixels on pages where patients enter health information.
See the full 12-week program →
Training and certification expectations
No credential is legally required to treat menopause, but patients and referral sources look for one, and your board expects demonstrated competence. The Menopause Society Certified Practitioner (MSCP) credential is open to licensed physicians, NPs, PAs, nurses, pharmacists and other clinicians who pass its examination, and runs on a three-year cycle maintained by continuing education or re-examination. The Society’s clinician’s guide and position statements are the working reference set. Budget for the exam and a structured menopause course before you see patients, and keep a record of the training behind your protocols.
Operations: EHR, labs, pharmacy, shipping and intake
The operating stack is lean: an EHR with integrated video, e-prescribing including EPCS, a templated menopause intake and a secure patient messenger. Labs run through a clinic account with a national laboratory and a local draw site; where direct-to-consumer ordering is permitted, patients can also bring recent results. Pharmacy routing splits into two lanes: approved products to the patient’s local or mail-order pharmacy, compounded preparations to a vetted compounding pharmacy that ships under its own nonresident licenses. Intake should capture a full history, a validated symptom score such as the Menopause Rating Scale, the contraindication screen and the patient’s goals.
Economics of monthly management
The shape is consistent across markets: a paid initial consultation, a lab fee, then a monthly or quarterly management fee covering visits, messaging, refills and dose adjustment, with medications paid separately.
| Item | Typical range (confirm for your market) |
|---|---|
| Initial consultation (45–60 minutes) | $199–$399 |
| Baseline labs (cash, through clinic account) | $75–$250 depending on panel |
| Monthly management fee | $79–$199 |
| Medications (paid to pharmacy) | Approved generics often $15–$80/month; compounded preparations vary |
| Typical patient lifetime | 12–36 months or longer with annual review |
On a $129 monthly fee, 10 active patients can mean roughly $1,300 a month in recurring revenue, 25 patients roughly $3,200, and 50 patients roughly $6,500, before consult and lab revenue and before costs. These are arithmetic illustrations, not projections.
Patient acquisition for a women’s hormone clinic
Search intent in this niche is specific: women search their symptoms (“night sweats at 47”, “is HRT safe now”), the therapy (“estradiol patch vs pill”, “testosterone for women”) and access (“online menopause clinic”). Long-form, guideline-anchored articles that answer those questions honestly, including the 2025 label changes explained plainly, earn trust and rank. A Google Business Profile is available where you have a physical address patients can visit; telehealth-only practices should confirm eligibility. Referrals come from primary care clinicians and gynecologists glad to hand off hormone management. Social content works when it is educational and fails when it drifts into product claims.
For OBGYNs adding telehealth hormone care to an existing practice
An established OBGYN practice is the natural home for this model: the patients already exist in the panel, the screening infrastructure is in place, and the gap is time, because a 15-minute insurance visit cannot hold a menopause conversation. A cash-pay telehealth arm run as a distinct service line, with its own consent, scheduling block and pricing, delivers the longer visits the care requires without displacing surgical and obstetric volume. Settle with counsel how the cash service stays separate from insurance-billed care and whether an NP or PA on the team runs day-to-day management.
The 12-week Clinic In A Box map applied to this specialty
Clinic In A Box™ is a private, 1-on-1, done-with-you 12-week build led by an operator-mentor who runs active telemedicine clinics in the US, Colombia and Australia. For a women’s hormone and menopause clinic the items land in the weeks shown.
- Weeks 1–4, Foundation. Patient avatar and scope; approved-first formulary and compounding exceptions; entity, licenses, collaboration agreements where required, DEA and any state registration; EHR with EPCS and the menopause intake, consent and contraindication screen; training plan and MSCP exam date.
- Weeks 5–8, Operations. Written protocols for initiation, titration, monitoring, testosterone dosing and lab triggers; lab account and draw-site map; two vetted pharmacies with nonresident licenses confirmed; refill workflow; service menu, pricing and payment processing; website reviewed against advertising rules.
- Weeks 9–12, Launch. Symptom-led search content and referral outreach; Google Business Profile where eligible; soft launch and first patients; retention tracking; a 90-day roadmap with a watch on the federal telemedicine rule and FDA label updates.
Who this is for, and who it is not for
It fits NPs, PAs and physicians who already care for midlife women, OBGYN and family practices adding a focused service line, and clinicians willing to study the guideline base and sit for certification. It does not fit anyone who wants to sell a one-size hormone kit, lead with pellets or compounded “custom” hormones, or prescribe testosterone to women for energy and weight claims the evidence does not support.
For the national compliance layer under this specialty, read the telemedicine hormone clinic compliance guide; for the full launch sequence, read how to start a telemedicine hormone clinic. Nurse practitioners can start with the nurse practitioner practice startup program page, physicians with the physician telemedicine practice launch program page, and anyone treating Texas patients should read the Texas telemedicine practice guide. The investment is $10,000 for two hours a week of direct work plus messaging between sessions; details are on the Clinic In A Box™ program page.
Frequently asked questions
Can I run a menopause clinic by telemedicine without ordering hormone labs?
For a woman over 45 with typical symptoms, current guidance supports a clinical diagnosis, and hormone levels rarely change the decision. Most clinics still order a modest safety panel before systemic therapy and use labs selectively for younger women, atypical presentations and testosterone monitoring.
Are compounded bioidentical hormones legal to prescribe through a telehealth clinic?
Generally yes when prescribed individually and dispensed by a properly licensed compounding pharmacy, but they are not FDA-approved, a 2020 National Academies report recommended limiting their use to narrow circumstances, and the FDA reopened the question in 2025. Lead with approved products and document the reason for any compounded preparation.
Can an NP prescribe testosterone to women by telemedicine?
In many states, subject to that state’s Schedule III prescriptive authority and any collaboration requirement, a DEA registration and current federal telemedicine rules, extended through the end of 2026 under a temporary rule. Use is off-label for women, so dosing, consent and monitoring must be documented. Confirm with your board and counsel.
Do I need Menopause Society certification to open the clinic?
No law requires it, but it is the recognized credential in the field, it is open to NPs, PAs, physicians and other licensed clinicians, and boards expect you to practice within demonstrated competence. Plan to earn it in the first year.
Request your free info session
The next step is a free 30-minute info session covering your credential, the states you want to serve, your formulary and testosterone decisions, and whether this is the right vehicle. Either way you leave with a clearer picture of what to do next. Call 844-734-2112 or use the form below.